These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 18349319)
1. Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3. Chang YC; Chen TC; Lee CT; Yang CY; Wang HW; Wang CC; Hsieh SL Blood; 2008 May; 111(10):5054-63. PubMed ID: 18349319 [TBL] [Abstract][Full Text] [Related]
2. Decoy receptor 3 enhances tumor progression via induction of tumor-associated macrophages. Tai SK; Chang HC; Lan KL; Lee CT; Yang CY; Chen NJ; Chou TY; Tarng DC; Hsieh SL J Immunol; 2012 Mar; 188(5):2464-71. PubMed ID: 22287720 [TBL] [Abstract][Full Text] [Related]
4. The arginine methyltransferase PRMT5 regulates CIITA-dependent MHC II transcription. Fan Z; Kong X; Xia J; Wu X; Li H; Xu H; Fang M; Xu Y Biochim Biophys Acta; 2016 May; 1859(5):687-96. PubMed ID: 26972221 [TBL] [Abstract][Full Text] [Related]
5. Tumor-mediated down-regulation of MHC class II in DC development is attributable to the epigenetic control of the CIITA type I promoter. Choi YE; Yu HN; Yoon CH; Bae YS Eur J Immunol; 2009 Mar; 39(3):858-68. PubMed ID: 19224634 [TBL] [Abstract][Full Text] [Related]
6. Decoy receptor 3 regulates the expression of various genes in rheumatoid arthritis synovial fibroblasts. Fukuda K; Miura Y; Maeda T; Takahashi M; Hayashi S; Kurosaka M Int J Mol Med; 2013 Oct; 32(4):910-6. PubMed ID: 23912906 [TBL] [Abstract][Full Text] [Related]
7. FoxO1 is a regulator of MHC-II expression and anti-tumor effect of tumor-associated macrophages. Yang JB; Zhao ZB; Liu QZ; Hu TD; Long J; Yan K; Lian ZX Oncogene; 2018 Mar; 37(9):1192-1204. PubMed ID: 29238041 [TBL] [Abstract][Full Text] [Related]
8. MHC class II transactivator is an in vivo regulator of osteoclast differentiation and bone homeostasis co-opted from adaptive immunity. Benasciutti E; Mariani E; Oliva L; Scolari M; Perilli E; Barras E; Milan E; Orfanelli U; Fazzalari NL; Campana L; Capobianco A; Otten L; Particelli F; Acha-Orbea H; Baruffaldi F; Faccio R; Sitia R; Reith W; Cenci S J Bone Miner Res; 2014 Feb; 29(2):290-303. PubMed ID: 24038328 [TBL] [Abstract][Full Text] [Related]
9. Nitric oxide inhibits INFgamma-induced increases in CIITA mRNA abundance and activation of CIITA dependent genes--class II MHC, Ii and H-2M. Class II TransActivator. Kielar ML; Sicher SC; Penfield JG; Jeyarajah DR; Lu CY Inflammation; 2000 Oct; 24(5):431-45. PubMed ID: 10921507 [TBL] [Abstract][Full Text] [Related]
10. Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen Inhibits Major Histocompatibility Complex Class II Expression by Disrupting Enhanceosome Assembly through Binding with the Regulatory Factor X Complex. Thakker S; Purushothaman P; Gupta N; Challa S; Cai Q; Verma SC J Virol; 2015 May; 89(10):5536-56. PubMed ID: 25740990 [TBL] [Abstract][Full Text] [Related]
11. IFN-gamma regulation of class II transactivator promoter IV in macrophages and microglia: involvement of the suppressors of cytokine signaling-1 protein. O'Keefe GM; Nguyen VT; Ping Tang LL; Benveniste EN J Immunol; 2001 Feb; 166(4):2260-9. PubMed ID: 11160280 [TBL] [Abstract][Full Text] [Related]
12. Differential selectivity of CIITA promoter activation by IFN-gamma and IRF-1 in astrocytes and macrophages: CIITA promoter activation is not affected by TNF-alpha. Nikcevich KM; Piskurich JF; Hellendall RP; Wang Y; Ting JP J Neuroimmunol; 1999 Oct; 99(2):195-204. PubMed ID: 10505975 [TBL] [Abstract][Full Text] [Related]
13. HLA-dependent tumour development: a role for tumour associate macrophages? Marchesi M; Andersson E; Villabona L; Seliger B; Lundqvist A; Kiessling R; Masucci GV J Transl Med; 2013 Oct; 11():247. PubMed ID: 24093459 [TBL] [Abstract][Full Text] [Related]
14. Malignant glioma cells use MHC class II transactivator (CIITA) promoters III and IV to direct IFN-gamma-inducible CIITA expression and can function as nonprofessional antigen presenting cells in endocytic processing and CD4(+) T-cell activation. Soos JM; Krieger JI; Stüve O; King CL; Patarroyo JC; Aldape K; Wosik K; Slavin AJ; Nelson PA; Antel JP; Zamvil SS Glia; 2001 Dec; 36(3):391-405. PubMed ID: 11746775 [TBL] [Abstract][Full Text] [Related]
15. Histone deacetylation, but not hypermethylation, modifies class II transactivator and MHC class II gene expression in squamous cell carcinomas. Kanaseki T; Ikeda H; Takamura Y; Toyota M; Hirohashi Y; Tokino T; Himi T; Sato N J Immunol; 2003 May; 170(10):4980-5. PubMed ID: 12734341 [TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus transcription activator Rta upregulates decoy receptor 3 expression by binding to its promoter. Ho CH; Hsu CF; Fong PF; Tai SK; Hsieh SL; Chen CJ J Virol; 2007 May; 81(9):4837-47. PubMed ID: 17301127 [TBL] [Abstract][Full Text] [Related]
17. Decoy receptor 3: an endogenous immunomodulator in cancer growth and inflammatory reactions. Hsieh SL; Lin WW J Biomed Sci; 2017 Jun; 24(1):39. PubMed ID: 28629361 [TBL] [Abstract][Full Text] [Related]
18. Capsaicin inhibits IFN-gamma-induced MHC class II expression by suppressing transcription of class II transactivator gene in murine peritoneal macrophages. Mahmoud ME; Nikami H; Shiina T; Takewaki T; Shimizu Y Int Immunopharmacol; 2010 Jan; 10(1):86-90. PubMed ID: 19825429 [TBL] [Abstract][Full Text] [Related]
19. Deregulated MHC class II transactivator expression leads to a strong Th2 bias in CD4+ T lymphocytes. Otten LA; Tacchini-Cottier F; Lohoff M; Annunziato F; Cosmi L; Scarpellino L; Louis J; Steimle V; Reith W; Acha-Orbea H J Immunol; 2003 Feb; 170(3):1150-7. PubMed ID: 12538670 [TBL] [Abstract][Full Text] [Related]
20. Decoy receptor 3 suppresses FasL-induced apoptosis via ERK1/2 activation in pancreatic cancer cells. Zhang Y; Li D; Zhao X; Song S; Zhang L; Zhu D; Wang Z; Chen X; Zhou J Biochem Biophys Res Commun; 2015 Aug; 463(4):1144-51. PubMed ID: 26102031 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]